Lv4
500 积分 2024-02-21 加入
Unveiling the effectiveness and safety spectrum of biologic therapies in psoriasis: a three-year real-world analysis
13天前
已完结
Clarifying psoriasis disease severity: A position statement from the National Psoriasis Foundation Medical Board
13天前
已完结
61865 Guselkumab demonstrates effectiveness regardless of disease duration: Week 76 results from the real-world G-EPOSS study
1个月前
已关闭
Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
1个月前
已完结
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
1个月前
已完结
Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
1个月前
已完结
Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment
1个月前
已完结
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)
1个月前
已完结
587 Higher IL-10+ T cell and treg cell counts in psoriatic skin are associated with super-response to guselkumab: Data from the phase 3 guide trial
1个月前
已完结
A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit
1个月前
已完结
皖公网安备34019202002308
